Enliven Therapeutics (ELVN) Short-term Investments (2019 - 2026)

Enliven Therapeutics (ELVN) has 8 years of Short-term Investments data on file, last reported at $320.2 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments changed N/A year-over-year to $320.2 million; the trailing twelve-month figure through Mar 2026 stood at $320.2 million (changed N/A YoY), and the FY2025 full-year result was $363.7 million, up 92.12% from the prior year.
• Short-term Investments eased to $320.2 million in Q1 2026, from $363.7 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $363.7 million in Q4 2025 to a low of $54000.0 in Q2 2024.
• A 5-year average of $134.4 million and a median of $152.6 million in 2023 frame the typical range for Short-term Investments.
• Across the five-year window, Short-term Investments jumped 2683.37% in 2023 and slumped 99.97% in 2024, its largest moves.
• Tracing ELVN's Short-term Investments over 5 years: stood at $6.8 million in 2022, then jumped by 2145.81% to $153.0 million in 2023, then increased by 23.73% to $189.3 million in 2024, then jumped by 92.12% to $363.7 million in 2025, then dropped by 11.96% to $320.2 million in 2026.
• Business Quant data shows ELVN's Short-term Investments at $320.2 million in Q1 2026, $363.7 million in Q4 2025, and $189.3 million in Q4 2024.